Apoptosis in amyotrophic lateral sclerosis--what is the evidence?
- PMID: 16033692
- DOI: 10.1016/S1474-4422(05)70142-3
Apoptosis in amyotrophic lateral sclerosis--what is the evidence?
Abstract
There is increasing evidence that a programmed mechanism of cell death resembling apoptosis is responsible for motor-neuron degeneration in amyotrophic lateral sclerosis. Our understanding of the cell-death pathway has come from studies of both experimental models and human tissue. Here we examine in detail the in vitro and in vivo evidence for and against apoptosis in amyotrophic lateral sclerosis, looking at morphological changes, caspase activation, alterations in Bcl-2 oncoproteins, involvement of death receptors, expression of apoptosis-related molecules, and the role of the p53 pathway. Finally, we present evidence of potential therapeutic agents that could modulate the apoptotic pathway in amyotrophic lateral sclerosis and slow disease progression.
Similar articles
-
Apoptosis in amyotrophic lateral sclerosis: a review of the evidence.Neuropathol Appl Neurobiol. 2001 Aug;27(4):257-74. doi: 10.1046/j.0305-1846.2001.00332.x. Neuropathol Appl Neurobiol. 2001. PMID: 11532157 Review.
-
Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.J Neurochem. 2005 Jun;93(5):1087-98. doi: 10.1111/j.1471-4159.2005.03077.x. J Neurochem. 2005. PMID: 15934930
-
Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway.Neurobiol Dis. 2000 Aug;7(4):406-15. doi: 10.1006/nbdi.2000.0295. Neurobiol Dis. 2000. PMID: 10964611
-
Programmed cell death in amyotrophic lateral sclerosis.J Clin Invest. 2003 Jan;111(2):153-61. doi: 10.1172/JCI17610. J Clin Invest. 2003. PMID: 12531867 Free PMC article. Review. No abstract available.
-
Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance.Neurologist. 2004 Jan;10(1):1-7. doi: 10.1097/01.nrl.0000106920.84668.37. Neurologist. 2004. PMID: 14720310 Review.
Cited by
-
Autologous treatment for ALS with implication for broad neuroprotection.Transl Neurodegener. 2022 Mar 11;11(1):16. doi: 10.1186/s40035-022-00290-5. Transl Neurodegener. 2022. PMID: 35272709 Free PMC article.
-
The human G93A-superoxide dismutase-1 mutation, mitochondrial glutathione and apoptotic cell death.Neurochem Res. 2009 Oct;34(10):1847-56. doi: 10.1007/s11064-009-9974-z. Epub 2009 Apr 28. Neurochem Res. 2009. PMID: 19399611 Review.
-
Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS).J Neurol. 2017 Aug;264(8):1763-1767. doi: 10.1007/s00415-017-8564-2. Epub 2017 Jul 15. J Neurol. 2017. PMID: 28711998
-
Conditioned medium from human gingival mesenchymal stem cells protects motor-neuron-like NSC-34 cells against scratch-injury-induced cell death.Int J Immunopathol Pharmacol. 2017 Dec;30(4):383-394. doi: 10.1177/0394632017740976. Epub 2017 Nov 15. Int J Immunopathol Pharmacol. 2017. PMID: 29140156 Free PMC article.
-
The toxic metal hypothesis for neurological disorders.Front Neurol. 2023 Jun 23;14:1173779. doi: 10.3389/fneur.2023.1173779. eCollection 2023. Front Neurol. 2023. PMID: 37426441 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous